Evidence map›Paper›PMID 30094685›Full record

ArticleRheumatology international2018

Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis.

Klaus Krüger, Ulrich von Hinüber, Florian Meier, Haijun Tian, Katharina Böhm, Steffen M Jugl, Kathrin Borchert, Dominic Meise, Christine König, Sebastian Braun

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2020
    Pooled it
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Klaus KrügerPraxiszentrum, St.-Bonifatius-Straße 5, 81541, Munich, Germany.
Ulrich von HinüberRheumapraxis Hildesheim, Bahnhofsplatz 5, 31134, Hildesheim, Germany.
Florian MeierWilhelm Loehe University of Applied Sciences (WLH), Merkurstraße 41, 90763, Fürth, Germany.
Haijun TianNovartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
Katharina BöhmNovartis Pharma GmbH, Roonstraße 25, 90429, Nuremberg, Germany.
Steffen M JuglNovartis Pharma AG, Lichtstraße 35, 4056, Basel, Switzerland.
Kathrin BorchertXcenda GmbH, Lange Laube 31, 30159, Hannover, Germany. kathrin.borchert@xcenda.de.ORCID http://orcid.org/0000-0003-2769-0075
Dominic MeiseXcenda GmbH, Lange Laube 31, 30159, Hannover, Germany.
Christine KönigXcenda GmbH, Lange Laube 31, 30159, Hannover, Germany.
Sebastian BraunXcenda GmbH, Lange Laube 31, 30159, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To compare healthcare resource utilization and costs between ankylosing spondylitis (AS) patients and a matched sample from the general population without AS covered by the German Statutory Health Insurance (SHI) system, a non-interventional retrospectively matched cohort analysis was conducted using anonymized SHI claims data. Data from January 1st, 2011 through December 31st, 2014 were analyzed. Individuals with a coded diagnosis of AS during the enrollment period comprising the full year of 2013 were directly matched (1:5) to individuals without AS diagnosis in the whole study period by age, gender, hospitalizations, and comorbidities. All-cause healthcare resource utilization and direct costs were analyzed for the year 2013. Statistical tests were applied to compare the differences between the two sampled populations. In 2013, 10,208 AS patients were identified and matched to a sample of 51,040 patients without AS from the general population. Healthcare resource utilization was significantly higher in all healthcare sectors (inpatient, outpatient, pharmaceuticals, remedies, devices and aids, and sick leave) in the AS cohort. Mean all-cause healthcare costs per patient were about €2475 higher in the AS cohort compared to the general population. Most important cost drivers were hospitalizations and pharmaceuticals in terms of bDMARDs prescribed in 10% of the patients. Real-world data from this German claims database analysis showed that AS is associated with a substantial incremental economic burden to the healthcare system.

Indexed as

Cost of IllnessHealth Care CostsAdministrative Claims, HealthcareAdolescentAdultAgedAged, 80 and overAge FactorsAmbulatory CareAntirheumatic AgentsComorbidityDatabases, FactualDrug CostsFemaleGermanyHospital CostsAntirheumatic AgentsAnkylosing spondylitisBurden of diseaseClaims dataCosts of illnessGermanyMatching

Identifiers

PMID30094685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.